NCT06639282 - Repurposing Siponimod for Alzheimer's Disease | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions

Alzheimer DiseaseMild Alzheimer DiseaseMCI With Increased Risk for Alzheimer DiseaseCognitive Impairment, Mild

Interventions

DRUG

Siponimod

Siponimod (formerly known as BAF312 and completed trial NCT #01665144) has been FDA approved since 2019 (IND #076122) for the treatment of multiple sclerosis. Siponimod is an immunomodulator that prevents the egression of T lymphocytes from peripheral lymphoid organs.

DRUG

Placebo

A placebo that resembles siponimod will be given once daily to participants randomly assigned into the placebo arm.

Trial Locations (1)

85013

St. Joseph's Hospital and Medical Center, Phoenix